Risk factors that may prompt additional consideration include: Active gastrointestinal symptoms (nausea, vomiting, abdominal pain) Recent dose increases or being in the dose-escalation phase Higher doses of semaglutide Known gastroparesis or other conditions affecting gastric emptying Obesity with GERD or hiatal hernia Based on the 2024 multi-society guidance, most patients can continue GLP-1 receptor agonists before elective procedures with appropriate risk assessment and mitigation strategies, rather than automatic postponement
Liraglutide reduces vascular damage, neuronal loss, and cognitive impairment in a mixed murine model of alzheimers disease and type 2 diabetes
Noh Y, Yin H, Yu OHY, Bitton A, Azoulay L
Whereas Orforglipron can be taken any time during the day with or without food
Updated May 19, 2026
Reviv Lounge combines this treatment with expert coaching to help you reach and maintain your goals